Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 7/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.43 |
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417460 | 0.92 | PARP10 (0.51) | PARP11PARP10GRM5PARP1 | |
| SCHEMBL12077946 | 0.84 | HSD11B1 (0.38) | PARP11PARP10GRM5PARP1HTR2C | |
| SCHEMBL23160144 | 0.83 | CES1 (0.48) | PARP11PARP10GRM5PARP1GSK3B | |
| SCHEMBL18305057 | 0.82 | PARP10 (0.57) | PARP11PARP10PARP1HTR2CHTR7 | |
| SCHEMBL315565 | 0.80 | MAOB (0.55) | GRM5MAOAMAOB | |
| SCHEMBL1471642 | 0.80 | MAOB (0.55) | GRM5MAOAMAOBSTS | |
| SCHEMBL3692167 | 0.79 | GRM5 (0.56) | PARP11PARP10GRM5PARP1 | |
| SCHEMBL30274539 | 0.78 | PARP10 (0.43) | PARP11PARP10GRM5PARP1GSK3B | |
| SCHEMBL4157926 | 0.77 | MAOB (0.57) | GRM5MAOAMAOBDRD2HTR1D | |
| SCHEMBL2089994 | 0.75 | DRD2 (0.42) | HTR2CHTR7HTR6MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| US-11725001-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-08-15 | — | — | US | disclosed |
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. | 2022-12-22 | — | — | US | disclosed |
| CN-114929691-A | Bicyclic compounds and uses thereof | 爱思开生物制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| EP-4039686-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021066578-A1 | BICYCLIC COMPOUND AND USE THEREOF | 에스케이바이오팜 주식회사 | 2021-04-08 | — | — | WO | disclosed |
| EP-2681206-B1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2014-02-20 | — | — | US | disclosed |
| EP-2681206-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8440652-B2 | MST1 kinase inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| WO-2012121992-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225449-A1 | Method and appraratus utilizing enzyme substrates producing slow diffusing fluorescent product appearances and chromogens, and use in combination with fast diffusing product appearances | ROTH GEOFFREY N (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | PARP11 78/4885PARP10 58/4885GRM5 97/4885 |
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | PARP11 1232/4885PARP10 1435/4885GRM5 2527/4885 |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | PARP11 78/4885PARP10 58/4885GRM5 97/4885 |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT8 | PARP11 99/4885PARP10 78/4885GRM5 144/4885 |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | PARP11 1232/4885PARP10 1435/4885GRM5 2527/4885 |
| US-11725001-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | PARP11 78/4885PARP10 58/4885GRM5 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.